 BURLINGAME, Calif. CHICAGO--BUSINESS WIRE--Humanigen, Inc. HGEN Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, and EVERSANA, a pioneer of next-generation services to the global life sciences industry, today announced that they are partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authoriz 